Investigational drug · Phase 2
TCMCB07
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cancer Weight Loss.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "TCMCB07"
First trial start
2025
Apr 28, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TCMCB07", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cancer Weight Loss
Approved drugs for the same conditions: Oncology · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "TCMCB07" as an intervention, largest first.
- Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing ChemotherapyPivotal-lookingRecruiting
Endevica BioIndustry
NCT06937177 · 120 participants (planned) · Start Apr 28, 2025 · Primary completion Oct 2027
Drug: TCMCB07; Placebo · For: Cancer Weight Loss
Sites: Tucson, Arizona; Los Angeles, California; Santa Monica, California · 26 sites in all
Endevica BioIndustry
NCT05529849 · 76 participants · Start Jul 12, 2022 · Primary completion Dec 12, 2022
Drug: TCMCB07; Placebo · For: Cachexia
Sites: Miami, Florida
Newest research
PubMed records naming it or its code names, newest first.
- Benzene metabolite-targeted gene ATF7IP2 drives glutamate metabolic reprogramming to promote acute myeloid leukemia initiation.
Zheng S · Toxicol Lett 2026
- Electroacupuncture alleviates blood-brain barrier disruption and neuroinflammation via astrocytic MC4R in a mouse model of multiple sclerosis.
Wang Y, Ma X, Qiao Z, et al. · J Neuroinflammation 2025
- Cachexia and Wasting in Chronic Illness: Regulatory and Clinical Trial Update.
Fioretti F, von Haehling S, Coats AJS, et al. · J Cachexia Sarcopenia Muscle 2025
- Melanocortin-4 receptor antagonist TCMCB07 alleviates chemotherapy-induced anorexia and weight loss in rats.
Zhu X, Potterfield R, Gruber KA, et al. · J Clin Invest 2024
- Safety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexia.
Axiak-Bechtel SM, Leach SB, Newton-Northup JR, et al. · J Vet Intern Med 2023
- Development of a Therapeutic Peptide for Cachexia Suggests a Platform Approach for Drug-like Peptides.
Gruber KA, Ji RL, Gallazzi F, et al. · ACS Pharmacol Transl Sci 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.